<DOC>
	<DOCNO>NCT03100838</DOCNO>
	<brief_summary>The purpose study measure amount study drug present blood administer generic version nifedipine extended-release tablet , 60 mg ( Valeant Pharmaceuticals , LLC ) brand-name version PROCARDIA XL extended-release tablet , 60 mg ( Pfizer Inc. ) individually presence stomach acid reduce drug ( antacid ) , omeprazole/sodium bicarbonate capsule , 40 mg/1100 mg ( generic ) separate occasion , empty stomach . This study also involve administration FDA-cleared capsule , SmartPill™ , measure stomach acid , prior study arm .</brief_summary>
	<brief_title>Drug Interaction With Proton Pump Inhibitors Nifedipine ER Tablets</brief_title>
	<detailed_description>A question arise generic oral extended-release ( ER ) product relate pH-dependent dissolution kinetics comparison reference list drug ( RLD ) . For example , poorly water-soluble drug presence pKa gastrointestinal ( GI ) pH range pH-dependent solubility dissolution behavior vivo drug release . In case , generic product utilizes different release mechanism could amplify reduce pH dependence ( e.g . osmotic pump RLD vs. matrix generic counterpart ) . This may render generic ER product less dependent gastric pH modification , commonly occur patient take concomitant over-the-counter ( OTC ) proton pump inhibitor ( PPIs ) treatment gastric acid-related disorder . It note PPIs ( e.g . lansoprazole , omeprazole , esomeprazole ) PPIs antacid ( e.g . omeprazole/sodium bicarbonate ) drastically elevate gastric pH , thus potentially change equilibrium solubility co-administered drug substance alter release profile . For instance , nifedipine calcium channel blocker , indicate long-term treatment hypertension angina . The drug substance weak acid ( pKa 3.9 ) practically insoluble water . Currently , one RLD oral ER nifedipine tablet base osmotic pump design ( Procardia XL ) generic counterpart ER nifedipine tablet employ matrix formulation design different RLD product . Due complicate release mechanism , quality attribute profile , vivo pharmacokinetics ( PK ) behavior ER product , FDA assess need drug-drug interaction study PPIs/antacids ( e.g . omeprazole/sodium bicarbonate ) generic nifedipine ER product base formulation design different RLD . To end , objective proposal investigate dependence vivo PK formulation design generic oral extended-release product comparison RLD co-administered PPIs/antacids . The outcome study help Agency advance understand product PK performance potential patient population abnormal gastric pH improve review standard equivalence category oral ER product necessary . The study result help Agency gain good understand drug-drug interaction oral modified-release product PPIs/antacids establish regulatory standard bioequivalence approach category generic oral ER product .</detailed_description>
	<mesh_term>Proton Pump Inhibitors</mesh_term>
	<mesh_term>Omeprazole</mesh_term>
	<mesh_term>Nifedipine</mesh_term>
	<criteria>1 . Healthy , males nonpregnant female volunteer , 18 55 year age , inclusive . 2 . Smoking status : Only nontobacco/nicotine user ( least 6 month prior clinical study ) eligible participate study . 3 . BMI within 18.535.0 kg/m² , inclusive . 4 . Healthy , accord medical history , ECG , vital sign , laboratory result physical examination determine PI/SubInvestigator . 5 . Ability comprehend inform nature study , assess BPSI staff . Capable give write informed consent prior receive study procedure . Must able communicate effectively clinic staff . 6 . Ability fast least 14 hour . 7 . Availability volunteer entire study duration willing adhere protocol requirement . 8 . Female subject must fulfill least one following : Be surgically sterile minimum 6 month ; Postmenopausal minimum 1 year ; Agree avoid pregnancy use medically acceptable method contraception least 30 day prior study 30 day study end ( last study procedure ) . Medically acceptable method contraception include nonhormonal contraceptive , intrauterine device , double barrier method ( condom foam vaginal spermicidal suppository , diaphragm spermicide ) . Complete abstinence alone use method contraception . 1 . Known history presence clinically significant hepatic , renal/genitourinary , gastrointestinal ( e.g. , gastrointestinal obstruction , gastrointestinal ulcer ) , cardiovascular ( e.g. , severe obstructive coronary artery disease , myocardial infarction , angina , heart failure ) , cerebrovascular , pulmonary , endocrine , immunological , musculoskeletal , neurological , psychiatric , dermatological hematological disease condition unless determine clinically significant PI/SubInvestigator . 2 . Clinically significant history presence clinically significant gastrointestinal pathology ( e.g . chronic diarrhea , inflammatory bowel disease ) , unresolved gastrointestinal symptom ( e.g . diarrhea , vomit , swallow disorder ) , condition know interfere absorption , distribution , metabolism excretion drug experience within 7 day prior first dosing , determine PI/SubInvestigator . 3 . QTc interval &gt; 430 millisecond male &gt; 450 millisecond female , unless deem otherwise PI/SubInvestigator . 4 . Abnormal clinical laboratory value , unless value deem PI/SubInvestigator `` Not Clinically Significant '' . 5 . Hemoglobin value less 11.5 g/dl . 6 . Abnormal vital sign ( blood pressure [ BP ] , heart rate [ HR ] , respiratory rate [ RR ] temperature ) measurement , unless deem otherwise PI/SubInvestigator . 7 . Presence clinically significant illness within 30 day prior first dosing , determine PI/SubInvestigator . 8 . Presence significant physical organ abnormality determine PI/SubInvestigator . 9 . Individuals implant portable electromechanical medical device cardiac pacemaker , defibrillator infusion pump . 10 . A positive test result follow : HIV , Hepatitis B surface antigen , Hepatitis C , drug abuse ( marijuana , amphetamine , barbiturate , cocaine , opiates , phencyclidine benzodiazepine ) , alcohol test cotinine . Positive pregnancy test female subject . 11 . Known history presence : Alcohol abuse dependence within one year prior first study period ; Drug abuse dependence ; Hypersensitivity idiosyncratic reaction nifedipine , omeprazole/sodium bicarbonate , excipients , and/or related substance ; Hypotension ; Bartter 's syndrome ; Gastric bezoar ; Crohn 's disease diverticulitis ; severe dysphagia food pill ; Food allergy and/or presence dietary restriction ; Severe allergic reaction ( e.g . anaphylactic reaction , angioedema ) . 12 . History intolerance and/or difficulty blood sample venipuncture . 13 . Abnormal diet pattern ( reason ) four week precede study , include fasting , high protein diet , vegan , etc . 14 . Individuals donate , day prior first study period : 50499 mL blood previous 30 day ; 500 mL previous 56 day . 15 . Donation plasma plasmapheresis within 7 day prior first study period . 16 . Individuals participate another clinical trial receive investigational drug within 30 day prior first study period . 17 . Use enzymemodifying drug and/or product , include strong inhibitor cytochrome P450 ( CYP ) enzymes ( e.g . cimetidine , fluoxetine , quinidine , fluconazole , ketoconazole , voriconazole , itraconazole , clarithromycin , erythromycin , nefazodone , atazanavir , saquinavir , indinavir , nelfinavir ) strong inducer CYP enzyme ( e.g . barbiturate , carbamazepine , glucocorticoid , phenytoin , St. John´s Wort rifampin ) previous 30 day first study period . 18 . Use drug , proton pump inhibitor , clopidogrel , tacrolimus , digoxin , cyclosporine , disulfiram , benzodiazepine , diazepam , warfarin , methotrexate , iron salt , erlotinib , mycophenolate mofetil ( MMF ) previous 30 day first study period , individual vitamin B12 deficiency ( longterm dosing ( 3 year ) omeprazole/sodium bicarbonateZegerid may lead vitamin B12 deficiency ) 19 . Individuals undergone gastrointestinal ( GI ) surgery within 3 month prior first study period , unless deem otherwise PI/SubInvestigator . 20 . Use prescription medication within 14 day prior first study period ( except contraceptive ) . 21 . Use overthecounter medication ( include oral multivitamin , herbal and/or dietary supplement and/or tea ) within 14 day prior first study period ( except spermicidal/barrier contraceptive product ) . 22 . Consumption food beverage contain grapefruit grapefruit juice and/or pomelo within 10 day prior first study period . 23 . Consumption food beverage contain caffeine/methylxanthines , poppy seed and/or alcohol within 48 hour dose . 24 . Use diuretic ( drug food , see Appendix D ) within 24 hour dose SmartPillTM . 25 . Individuals undergone major surgery within 6 month prior start study , unless deem otherwise PI/SubInvestigator . 26 . Difficulty swallow whole tablet large capsule . 27 . Have tattoo body pierce within 30 day prior first study period study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Proton Pump Inhibitor</keyword>
	<keyword>Bioequivalence</keyword>
	<keyword>Drug-Drug Interaction</keyword>
	<keyword>Modified Release</keyword>
	<keyword>Nifedipine</keyword>
</DOC>